Anika Therapeutics (ANIK) Misses Q1 EPS by 62c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $16.34 --0%
EPS Growth %: +115.4%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
CCEL, SLP, TMQ, More
EPS Growth %: +115.4%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.46), $0.62 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $21.26 million versus the consensus estimate of $24.34 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
- Alibaba (BABA) PT Lowered to $170 at HSBC
- GitLab updates consumption revenue metric, CRR surpasses $20M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
